Targeting the genetic cause of DRPLA
A project targeting the genetic cause of DRPLA, a rare form of ataxia, has received further funding from Ataxia UK.
Targeting the genetic cause of DRPLA Read More »
DRPLA
Euro-ataxia publishes patient charter outlining mission for patient involvement in ataxia clinical trials
At the Euro-ataxia meeting in Frankfurt on 9th November 2018 a workshop was held to discuss the role of patients and patient groups in research. This led to the creation of the Euro-ataxia patient charter which has now been published.
The Neurological Alliance Report: Neuro Patience
In July 2019, The Neurological Alliance published the results of the 2018/19 National Neurology Patient Experience Survey.
The Neurological Alliance Report: Neuro Patience Read More »
Euro-ataxia annual meeting
Ataxia UK’s Head of Research Julie Greenfield reports on the 2018 Euro-ataxia annual conference held in Frankfurt.
Euro-ataxia annual meeting Read More »
Ataxia UK medical guidelines published in peer-reviewed journal
We are delighted that on 20 February 2019 the Ataxia UK Medical Guidelines were published in the Orphanet Journal of Rare Diseases.
Ataxia UK medical guidelines published in peer-reviewed journal Read More »
Euro-ataxia conference 2018
Euro-ataxia held the latest annual meeting on 9-10th November 2018 in Frankfurt, Germany, hosted by the German ataxia charity DHAG, organised by Ataxia UK and sponsored by BioMarin.
Euro-ataxia conference 2018 Read More »
Final draft of National Genomic Test Directory includes hereditary ataxia
NHS England has included hereditary ataxia in the final draft of the National Genomic Test Directory for rare and inherited disorders and cancer
Final draft of National Genomic Test Directory includes hereditary ataxia Read More »
Research News – May and June 2018
Catch up on the latest research news!
Research News – May and June 2018 Read More »
FDA Orphan Drug Designation for Spinocerebellar
IntraBio, a U.K. based biopharmaceutical company, has received an Orphan Drug Designation from the US Food and Drug Administration (FDA) for its lead compound (IB1000) for the treatment of spinocerebellar
FDA Orphan Drug Designation for Spinocerebellar Read More »
Latest Research News – December 2016
Read up on the latest research news!
Latest Research News – December 2016 Read More »
European Reference Networks
the European Commission approves the first 23 European Reference Networks for rare diseases (ERNs), including the one covering the ataxias.
European Reference Networks Read More »
Latest Research News – July and August 2016
Read up on the latest research news!
Latest Research News – July and August 2016 Read More »
